Clinical trials in Nantes – page 7

954 clinical trials in Nantes, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Nantes at a glance

954

clinical trials

Research sites2

Quick filters

954 trials in Nantes

Open in trial search

Non-small cell lung cancer

Recruiting

Comparing sotorasib and pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drugNo placebo

Comparing sotorasib and pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Amgen Inc.

Contact Research Centre

Neoplasm malignant

Recruiting

A study of YL201 and atezolizumab for patients with advanced solid tumors

Registered drugNo placebo

A study of YL201 and atezolizumab for patients with advanced solid tumors

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:Medilink Therapeutics (Suzhou) Co. Ltd.

Contact Research Centre

Type 1 diabetes mellitus+1

Recruiting

Study of anakinra and a drug combination to prevent blood clots in patients receiving a pancreatic transplant

Registered drugNo placebo

Study of anakinra and a drug combination to prevent blood clots in patients receiving a pancreatic transplant

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Anakinra
Sponsor:Centre Hospitalier Universitaire De Nantes

Contact Research Centre

Gastric cancer+2

Recruiting

A study of pumitamig and a drug combination versus nivolumab and a drug combination for patients with untreated advanced or metastatic stomach or esophageal cancer

Registered drugNo placebo

A study of pumitamig and a drug combination versus nivolumab and a drug combination for patients with untreated advanced or metastatic stomach or esophageal cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Colorectal cancer metastatic

Recruiting

A study of pumitamig and a drug combination versus bevacizumab and a drug combination for patients with untreated, unresectable, or metastatic colorectal cancer

Registered drugNo placebo

A study of pumitamig and a drug combination versus bevacizumab and a drug combination for patients with untreated, unresectable, or metastatic colorectal cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Mantle cell lymphoma recurrent+1

Recruiting

A study to compare glofitamab against a drug combination for patients with relapsed or refractory mantle cell lymphoma

Registered drugNo placebo

A study to compare glofitamab against a drug combination for patients with relapsed or refractory mantle cell lymphoma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Glofitamab
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Hormone-refractory prostate cancer

Recruiting

Study of AMO959, lutetium (177Lu) vipivotide tetraxetan, and a drug combination for adults with advanced prostate cancer.

Registered drugNo placebo

Study of AMO959, lutetium (177Lu) vipivotide tetraxetan, and a drug combination for adults with advanced prostate cancer.

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Abiraterone
Sponsor:Novartis Pharma AG

Contact Research Centre

Hidradenitis

Recruiting

A safety and efficacy study of SAR445399 in adults with moderate to severe hidradenitis suppurativa

Investigational

A safety and efficacy study of SAR445399 in adults with moderate to severe hidradenitis suppurativa

Investigational

France

Participants:18–64 years · 65+ years
Substances:SAR445399
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Chronic kidney disease+1

Recruiting

A study to evaluate the effect of orforglipron on cardiovascular health in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease

Investigational

A study to evaluate the effect of orforglipron on cardiovascular health in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease

Investigational

France

Participants:18–64 years · 65+ years
Sponsor:Eli Lilly & Co.

Contact Research Centre

HIV infection

Recruiting

A study of islatravir and ulonivirine for adults with HIV who have not received previous treatment

Registered drug

A study of islatravir and ulonivirine for adults with HIV who have not received previous treatment

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Emtricitabine
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Clostridium difficile infection

Recruiting

A study to evaluate the effectiveness of AZD5148 in preventing the recurrence of Clostridioides difficile infection in adults.

Investigational

A study to evaluate the effectiveness of AZD5148 in preventing the recurrence of Clostridioides difficile infection in adults.

Investigational

France

Participants:18–64 years · 65+ years
Substances:AZD5148
Sponsor:AstraZeneca AB

Contact Research Centre

Acute myeloid leukaemia

Recruiting

Study of ziftomenib with drug combinations for adults with newly diagnosed acute myeloid leukemia with NPM1 or KMT2A genetic changes

Registered drug

Study of ziftomenib with drug combinations for adults with newly diagnosed acute myeloid leukemia with NPM1 or KMT2A genetic changes

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Azacitidine
Sponsor:Kura Oncology Inc.

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Nantes

What the registry says about research in the country

01 Oncology and Hematology

Advanced research focusing on multiple myeloma, leukemia, and various lymphomas. Studies are evaluating novel treatment combinations and therapeutic approaches for blood cancers.

Multiple Myeloma Treatments
Lymphoma Therapies
Leukemia Management

Innovative trials exploring combinations of targeted therapies and immunotherapies to improve patient outcomes.

02 Infectious Diseases

Comprehensive studies on preventive measures against viral infections, including trials for vaccines targeting CMV, yellow fever, and mpox.

Vaccine Development
Viral Prevention
Immunization Studies

Focus on developing and evaluating new vaccine formulations and delivery methods.

03 Autoimmune Conditions

Research investigating treatments for inflammatory bowel diseases and multiple sclerosis, including innovative approaches like fecal microbiota transplantation.

Crohn's Disease
Ulcerative Colitis
MS Treatment Strategies

Exploring novel therapeutic options and treatment de-escalation strategies.

04 Critical Care Medicine

Studies addressing postoperative care and management of severe conditions in intensive care settings, including burns and immune suppression.

Post-Surgery Care
Burn Treatment
ICU Interventions

Evaluating new approaches to improve patient comfort and outcomes in critical care.

Back to France All countries